Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.97
Handel nachbörslich:
4.99
4.99
+
Schlusskurs vom Vortag:
$4.97
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$48.77M
Einnahmen:
$21.73M
Nettoeinkommen (Verlust:
$-91.17M
KGV:
0.00
EPS:
-0.74
Netto-Cashflow:
$-286.43M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$15.40
Bluebird Bio Inc Stock (BLUE) Company Profile
Firmenname
Bluebird Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Vergleichen Sie BLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
0.00 | 48.77M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.21 | 101.15B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.14 | 61.07B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.59 | 59.35B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.83 | 46.29B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.27 | 35.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-11-15 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Bestätigt | Barclays | Equal Weight |
| 2021-11-08 | Bestätigt | Canaccord Genuity | Hold |
| 2021-11-08 | Herabstufung | Goldman | Neutral → Sell |
| 2021-11-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Bestätigt | Wedbush | Neutral |
| 2021-11-08 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-08-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Fortgesetzt | William Blair | Mkt Perform |
| 2021-08-09 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-03-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-02-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-02-16 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Eingeleitet | Mizuho | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-27 | Hochstufung | Stifel | Hold → Buy |
| 2020-02-19 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-02-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Hold |
| 2019-08-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Hochstufung | Maxim Group | Hold → Buy |
Alle ansehen
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
Death Cross: Does bluebird bio Inc. have strong fundamentals2025 Market Trends & Safe Investment Capital Preservation Plans - خودرو بانک
Short Covering: Is bluebird bio Inc being accumulated by smart money2025 Market Trends & Reliable Intraday Trade Alerts - خودرو بانک
Portfolio Recap: Is bluebird bio Inc a good ESG investment2025 Market Sentiment & Stock Timing and Entry Methods - خودرو بانک
bluebird bio says seeking more cash to achieve cash flow break-even - MSN
Adeno Associated Virus (AVV) Vectors In Gene Therapy Market - openPR.com
Real time social sentiment graph for bluebird bio Inc.July 2025 Momentum & Short-Term Swing Trade Alerts - Newser
Key metrics from bluebird bio Inc.’s quarterly dataStop Loss & Weekly Top Stock Performers List - Newser
Does bluebird bio Inc. have strong fundamentalsGap Up & Daily Entry Point Trade Alerts - خودرو بانک
Analyzing drawdowns of bluebird bio Inc. with statistical toolsJuly 2025 Trends & Stock Portfolio Risk Management - Newser
Can bluebird bio Inc. outperform in the next rallyQuarterly Trade Review & Weekly Watchlist for Consistent Profits - خودرو بانک
bluebird bio Inc. stock volume spike explainedWeekly Trading Summary & Consistent Return Investment Signals - Newser
Risk vs reward if holding onto bluebird bio Inc.Portfolio Risk Report & Safe Entry Zone Tips - Newser
Technical analysis overview for bluebird bio Inc. stockJuly 2025 Sentiment & Technical Confirmation Alerts - Newser
Can trapped investors hope for a rebound in bluebird bio Inc.2025 Big Picture & Weekly High Return Opportunities - Newser
Published on: 2025-09-05 06:20:06 - Newser
Comparing bluebird bio Inc. in custom built stock radarsLong Setup & Real-Time Volume Spike Alerts - Newser
Top chart patterns to watch in bluebird bio Inc.July 2025 Momentum & AI Powered Market Trend Analysis - Newser
Detecting price anomalies in bluebird bio Inc. with AITrade Risk Summary & Weekly Top Gainers Trade List - Newser
What indicators show strength in bluebird bio Inc.Market Performance Summary & Risk Managed Trade Strategies - Newser
Analyzing net buyer seller activity in bluebird bio Inc.July 2025 Institutional & Long-Term Investment Growth Plans - Newser
Applying sector rotation models to bluebird bio Inc.Day Trade & AI Powered Market Trend Analysis - Newser
What to do if you’re stuck in bluebird bio Inc.Market Growth Review & Weekly Return Optimization Alerts - Newser
Published on: 2025-09-03 04:16:36 - Newser
What moving averages say about bluebird bio Inc.July 2025 Decliners & Accurate Technical Buy Alerts - Newser
Tick level data insight on bluebird bio Inc. volatilityJuly 2025 Spike Watch & Low Risk High Win Rate Picks - Newser
How to build a custom watchlist for bluebird bio Inc.July 2025 Levels & Accurate Intraday Trading Signals - Newser
Intraday pattern recognizer results for bluebird bio Inc.July 2025 Pullbacks & Low Volatility Stock Suggestions - Newser
Will bluebird bio Inc. stock recover after earningsRisk Management & Long-Term Capital Growth Ideas - خودرو بانک
Returns Recap: Does bluebird bio Inc. have pricing powerMarket Performance Recap & Detailed Earnings Play Alerts - خودرو بانک
What candlestick patterns are forming on bluebird bio Inc.Trade Entry Summary & Daily Growth Stock Investment Tips - Newser
Rally Mode: Can bluebird bio Inc. benefit from deglobalizationJuly 2025 Reactions & Accurate Intraday Trade Tips - خودرو بانک
Technical signs of recovery in bluebird bio Inc.2025 Year in Review & Weekly Top Gainers Alerts - Newser
Finanzdaten der Bluebird Bio Inc-Aktie (BLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.33%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):